Clinical Trial Update: Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating add-on dapagliflozin for patients with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Damanhour University | Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2 | Phase 2 | Status: UNKNOWN